Cortexyme/$QNCX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cortexyme
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Ticker
$QNCX
Sector
Primary listing
Employees
36
Headquarters
Website
Cortexyme Metrics
BasicAdvanced
$192M
-
-$1.21
1.15
-
Price and volume
Market cap
$192M
Beta
1.15
52-week high
$3.58
52-week low
$0.72
Average daily volume
548K
Financial strength
Current ratio
1.121
Quick ratio
1.048
Long term debt to equity
33.9
Total debt to equity
1,699.056
Interest coverage (TTM)
-45.74%
Profitability
EBITDA (TTM)
-41.683
Effective tax rate (TTM)
-0.13%
Management effectiveness
Return on assets (TTM)
-22.10%
Return on equity (TTM)
-247.78%
Valuation
Price to book
177.54
Price to tangible book (TTM)
315.47
Price to free cash flow (TTM)
-4.171
Free cash flow yield (TTM)
-23.98%
Free cash flow per share (TTM)
-0.827
Growth
Earnings per share change (TTM)
-3.29%
3-year earnings per share growth (CAGR)
-17.69%
Cortexyme News
AllArticlesVideos
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Business Wire2 weeks ago
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Business Wire2 weeks ago
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cortexyme stock?
Cortexyme (QNCX) has a market cap of $192M as of November 28, 2025.
What is the P/E ratio for Cortexyme stock?
The price to earnings (P/E) ratio for Cortexyme (QNCX) stock is 0 as of November 28, 2025.
Does Cortexyme stock pay dividends?
No, Cortexyme (QNCX) stock does not pay dividends to its shareholders as of November 28, 2025.
When is the next Cortexyme dividend payment date?
Cortexyme (QNCX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cortexyme?
Cortexyme (QNCX) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.